7-(2,6-difluoro-3,5-dimethoxyphenyl)-2-[(3-hydroxyazetidin-1-yl)methyl]-9,9-dimethyl-3,6,7,9-tetrahydro-8H-pyrrolo[2,3-c]-2,7-naphthyridin-8-one | 1513858-58-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 7-(2,6-difluoro-3,5-dimethoxyphenyl)-2-[(3-hydroxyazetidin-1-yl)methyl]-9,9-dimethyl-3,6,7,9-tetrahydro-8H-pyrrolo[2,3-c]-2,7-naphthyridin-8-one
• 英文别名: US10131667, Example 206；7-(2,6-difluoro-3,5-dimethoxyphenyl)-2-[(3-hydroxyazetidin-1-yl)methyl]-9,9-dimethyl-3,6-dihydropyrrolo[2,3-c][2,7]naphthyridin-8-one
• CAS: 1513858-58-6
• 化学式: C₂₄H₂₆F₂N₄O₄
• 分子量: 472.492
• InChiKey: AJHOJMJHJXJSEG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  34
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  90.9
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS
  申请人：Incyte Corporation

  公开号：US20170137424A1

  公开（公告）日：2017-05-18

  The present invention relates to tricyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.

  本发明涉及三环化合物以及其药物组成物，它们是一种或多种FGFR酶的抑制剂，可用于治疗与FGFR相关的疾病，如癌症。
• Substituted tricyclic compounds as FGFR inhibitors
  申请人：Incyte Corporation

  公开号：US11053246B2

  公开（公告）日：2021-07-06

  The present invention relates to tricyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.

  本发明涉及三环化合物及其药物组合物，它们是一种或多种表皮生长因子受体酶的抑制剂，可用于治疗表皮生长因子受体相关疾病，如癌症。
• US9611267B2
  申请人：——

  公开号：US9611267B2

  公开（公告）日：2017-04-04
• [EN] SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS<br/>[FR] COMPOSÉS TRICYCLIQUES SUBSTITUÉS UTILISÉS COMME INHIBITEURS DE FGFR
  申请人：INCYTE CORP

  公开号：WO2014007951A2

  公开（公告）日：2014-01-09

  The present invention relates to tricyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.